Targeting ligands involved in those interactions with monoclonal antibodies (mAb) has proven to be effective in animal and human tumor models, and immune checkpoint blockade (ICB) with anti-PD-L1, anti-PD-1, or both mAbs is currently regarded as standard therapy for many advanced stage solid malignancies. The gene discussed is CD274; the disease is neoplasm.